COMMUNIQUÉS West-GlobeNewswire

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
08/11/2024
ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/11/2024
WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]
Aptose Reports Results for the Third Quarter 2024
08/11/2024
Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly Diagnosed AML SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ [...]
Novo Nordisk A/S - share repurchase programme
08/11/2024
Bagsværd, Denmark, 8 November 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase [...]
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
08/11/2024
Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of [...]
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
08/11/2024
WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T [...]
Extendicare Announces New $275 Million Senior Secured Credit Facility
08/11/2024
MARKHAM, Ontario, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that it has entered into a new senior secured credit facility for $275.0 million (the “ [...]
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
08/11/2024
Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and KEYTRUDA ® ( [...]
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
08/11/2024
Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk WALTHAM, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company [...]
Pearson Medical Technologies Introduces m:Print Bar Code Labeling Software v4 for Pharmacy Drug Supply Chain Security Act (DSCSA) Compliance
08/11/2024
ALEXANDRIA, La., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Pearson Medical Technologies announces the international release of m:Print® Bar Code Labeling Software Version 4 , a powerful new upgrade of its industry-leading [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
08/11/2024
Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024
08/11/2024
Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024
08/11/2024
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing market: [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024
08/11/2024
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : [...]
BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences
08/11/2024
8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of T he NGAL Test to Clinicians at Major Healthcare Conferences COPENHAGEN, DENMARK and BOSTON [...]
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
08/11/2024
New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy. Predictive biomarkers correlated [...]
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
08/11/2024
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where [...]
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
08/11/2024
The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed recognizes the [...]
Medigene Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities at Cell 2024
08/11/2024
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & Development Presentations and seminars highlighted [...]

Pages